Track topics on Twitter Track topics that are important to you
Janssen has announced that it has suffered a knockback to its plans to commercialise sirukumab in the US in the rheumatoid arthritis (RA) space, as the FDA refused to recommend the drug for the treatment of moderate to severely active forms of the disease in patients for whom disease modifying anti-rheumatic drugs are not applicable.
Original Article: FDA turns down Janssen's sirukumab for rheumatoid arthritisNEXT ARTICLE
Arthroplasty Joint Disorders Orthopedics Spinal Cord Disorders Orthopedics is the science or practice of correcting deformities caused by disease or damage to the bones and joints of the skeleton. This specialized branch of surgery may ...
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...